VNOV (VitaNova Life Sciences) Beginning Cash Position: $1.17 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VNOV VitaNova Life Sciences Corp VNOV
51 GF Score
Price $1.38
GF Value $5.95
! 1 Warning Sign
View Full Analysis

What is VitaNova Life Sciences Beginning Cash Position?

VitaNova Life Sciences VNOV 51 Beginning Cash Position is $1.17 Mil as of Apr. 2026. GuruFocus rates VNOV with a GF Score™ of 51/100 and a GF Value™ of $5.95. The stock has 1 warning sign investors should review.

VitaNova Life Sciences's Beginning Cash Position for the quarter that ended in Apr. 2026 was $1.17 Mil.

VitaNova Life Sciences's quarterly Beginning Cash Position increased from Oct. 2025 ($1.05 Mil) to Jan. 2026 ($1.26 Mil) but then declined from Jan. 2026 ($1.26 Mil) to Apr. 2026 ($1.17 Mil).

VitaNova Life Sciences's annual Beginning Cash Position increased from Apr. 2024 ($0.01 Mil) to Apr. 2025 ($0.59 Mil) and increased from Apr. 2025 ($0.59 Mil) to Apr. 2026 ($0.78 Mil).

VitaNova Life Sciences Beginning Cash Position Related Terms

VitaNova Life Sciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for VitaNova Life Sciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VitaNova Life Sciences Beginning Cash Position Chart

VitaNova Life Sciences Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.02 0.01 0.59 0.78

VitaNova Life Sciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.78 1.05 1.26 1.17
VNOV
51GF Score
VitaNova Life Sciences Corp VNOV
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VitaNova Life Sciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $1.17 Mil mean?
VitaNova Life Sciences (VNOV) has a Beginning Cash Position of $1.17 Mil as of Apr. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on VitaNova Life Sciences and its competitors.
Is VitaNova Life Sciences' Beginning Cash Position too high?
VitaNova Life Sciences' current Beginning Cash Position is $1.17 Mil. Overall, VitaNova Life Sciences has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does VitaNova Life Sciences' Beginning Cash Position compare to HKPD and COSM?
VitaNova Life Sciences' Beginning Cash Position of $1.17 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Distribution company?
A good Beginning Cash Position depends on the Medical Distribution industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on VitaNova Life Sciences and its competitors. VitaNova Life Sciences's current Beginning Cash Position is $1.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VitaNova Life Sciences stock overvalued right now?
VitaNova Life Sciences (VNOV) has a current Beginning Cash Position of $1.17 Mil. The stock's GF Value™ is $5.95, compared to a current price of $1.38 — trading 76.8% below its estimated fair value. The current Beginning Cash Position is $1.17 Mil. VitaNova Life Sciences' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For VitaNova Life Sciences (VNOV), the current Beginning Cash Position is $1.17 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VitaNova Life Sciences (VNOV) Overvalued in 2026?

Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued. The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.

Key valuation signals for VNOV:

  • Beginning Cash Position: $1.17 Mil
  • GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VitaNova Life Sciences Business Description

Address 30 E Broadway, Suite 603, New York, NY, USA, 10002
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score

Get the complete analysis for VNOV

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.38
Price
$5.95
GF Value